NVO Stock Price and Chart — NYSE:NVO

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

Key facts today

Novo Nordisk (NOVO_B) cut its full-year sales and profit forecast for the second time in 2025. CEO Lars Fruergaard Jørgensen resigned, causing a 25% drop in pre-market trading.

The 2nd U.S. Circuit Court of Appeals has reinstated a lawsuit against Novo Nordisk, allowing health centers to pursue claims of price-fixing on diabetes drugs under the federal '340B' program.

Novo Nordisk A/S faces a securities fraud investigation linked to a class action lawsuit from May 7 to July 28, 2025, alleging misleading statements about compounded GLP-1 drugs.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NVO.